TG Therapeutics: 'Strong Buy' Amid BRIUMVI Expansion Win And Boosted 2026 Outlook

The market is likely still underpricing how quickly a successful dosing simplification can change the competitive math in RMS: if the lower-burden regimen materially improves prescriber convenience, the revenue impact is not linear but can inflect through higher persistence, easier payer justification, and faster share capture from infusion-heavy peers. That creates a second-order winner set beyond the obvious single-name upside: infusion centers, specialty pharmacies, and payers that favor lower total treatment friction should lean toward the product, while competing anti-CD20 franchises face a pressure point on workflow and patient adherence rather than just efficacy.

The key near-term catalyst is not just the guidance raise, but whether the company can convert it into a higher-quality beat-and-raise cadence over the next 2-3 quarters. If quarterly growth stays >50% and trial data support label expansion, the stock can rerate from "commercial story" to "durable platform asset," which is typically worth a multiple turn in small-cap biotech. The risk is that guidance momentum can mask deceleration: once the base gets larger, any moderation in new starts, payer pushback, or infusion capacity constraints will be punished quickly, especially if investors extrapolate peak-growth assumptions too far.

Consensus seems to be treating this as a straightforward growth win, but the more interesting question is whether the market is underestimating how much the expanded dosing label could widen the addressable prescriber base. If the regimen lowers operational burden enough, the upside is less about incremental share in existing centers and more about unlocking physicians who previously avoided the brand due to complexity. The flip side is that if ENHANCE supports only a modest commercial benefit, the multiple may already discount the best-case scenario, leaving the stock vulnerable to an over-earnings response once expectations reset.